FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570220621> ?p ?o ?g. }

• W1570220621 endingPage "6" @default.
• W1570220621 startingPage "900" @default.
• W1570220621 abstract "Patients treated with total knee arthroplasty are at high risk for the development of venous thromboembolism postoperatively. This study compared the efficacy and safety of two common thromboprophylactic agents, enoxaparin (a low-molecular-weight heparin) and warfarin.Three hundred and forty-nine patients were included in a prospective, randomized, multicenter, open-label, parallel-group clinical trial. Treatment with enoxaparin (30 mg, administered subcutaneously twice daily) or warfarin (adjusted to an international normalized ratio of 2 to 3) was initiated during the immediate postoperative period, within eight hours after the surgery, and was continued for four to fourteen days. Venous thromboembolism was defined as deep-vein thrombosis documented by contrast venography, symptomatic deep-vein thrombosis documented by lower-extremity ultrasonography, or symptomatic pulmonary embolism confirmed by a positive lung scan or pulmonary angiography.In the all-treated-patients group, eighty (45%) of the 176 warfarin-treated patients had venous thromboembolism: fifty-nine (34%) had distal deep-vein thrombosis; twenty (11%), proximal deep-vein thrombosis; and one (0.6%), pulmonary embolism. Venous thromboembolism developed in significantly fewer (p = 0.0001) enoxaparin-treated patients (forty-four of 173; 25%): forty-one (24%) had distal deep-vein thrombosis, three (2%) had proximal deep-vein thrombosis, and none had pulmonary embolism. The enoxaparin-treated patients also had a significantly lower prevalence of proximal deep-vein thrombosis (p = 0.002). The estimated odds for the development of venous thromboembolism were 2.52 times greater (95% confidence interval, 2.00 to 3.19) with warfarin than they were with enoxaparin. Major hemorrhage occurred in four warfarin-treated patients and nine enoxaparin-treated patients; with the numbers available, this difference was not significant (p = 0.17). Clinically important operative-site hemorrhage occurred in six (3%) of the warfarin-treated patients and twelve (7%) of the enoxaparin-treated patients (p = 0.15).A fixed 30-mg subcutaneous dose of enoxaparin, administered twice daily, with the first dose administered within eight hours after the completion of surgery, was significantly more effective than adjusted-dose warfarin in reducing the occurrence of asymptomatic venous thromboembolism, including proximal deep-vein thrombosis, in patients undergoing total knee arthroplasty. With the numbers available, there was no significant difference between groups with regard to the occurrence of major hemorrhagic complications; however, the rate of overall hemorrhagic complications was higher in the enoxaparin group." @default.
• W1570220621 created "2016-06-24" @default.
• W1570220621 creator A5005384270 @default.
• W1570220621 creator A5018217171 @default.
• W1570220621 creator A5023161395 @default.
• W1570220621 creator A5045569384 @default.
• W1570220621 creator A5053751281 @default.
• W1570220621 creator A5064847807 @default.
• W1570220621 creator A5075691962 @default.
• W1570220621 creator A5089317773 @default.
• W1570220621 date "2001-06-01" @default.
• W1570220621 modified "2023-09-29" @default.
• W1570220621 title "Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin." @default.
• W1570220621 cites W1908679943 @default.
• W1570220621 cites W1964159013 @default.
• W1570220621 cites W2060188995 @default.
• W1570220621 cites W2066160685 @default.
• W1570220621 cites W2073265922 @default.
• W1570220621 cites W2093101608 @default.
• W1570220621 cites W2137279768 @default.
• W1570220621 cites W2166091057 @default.
• W1570220621 cites W2265007974 @default.
• W1570220621 cites W2289173900 @default.
• W1570220621 cites W2326914415 @default.
• W1570220621 cites W2341200743 @default.
• W1570220621 cites W2419582510 @default.
• W1570220621 cites W4246604215 @default.
• W1570220621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11407799" @default.
• W1570220621 hasPublicationYear "2001" @default.
• W1570220621 type Work @default.
• W1570220621 sameAs 1570220621 @default.
• W1570220621 citedByCount "62" @default.
• W1570220621 countsByYear W15702206212012 @default.
• W1570220621 countsByYear W15702206212013 @default.
• W1570220621 countsByYear W15702206212014 @default.
• W1570220621 countsByYear W15702206212015 @default.
• W1570220621 countsByYear W15702206212016 @default.
• W1570220621 countsByYear W15702206212017 @default.
• W1570220621 countsByYear W15702206212018 @default.
• W1570220621 countsByYear W15702206212019 @default.
• W1570220621 countsByYear W15702206212020 @default.
• W1570220621 countsByYear W15702206212021 @default.
• W1570220621 countsByYear W15702206212022 @default.
• W1570220621 countsByYear W15702206212023 @default.
• W1570220621 crossrefType "journal-article" @default.
• W1570220621 hasAuthorship W1570220621A5005384270 @default.
• W1570220621 hasAuthorship W1570220621A5018217171 @default.
• W1570220621 hasAuthorship W1570220621A5023161395 @default.
• W1570220621 hasAuthorship W1570220621A5045569384 @default.
• W1570220621 hasAuthorship W1570220621A5053751281 @default.
• W1570220621 hasAuthorship W1570220621A5064847807 @default.
• W1570220621 hasAuthorship W1570220621A5075691962 @default.
• W1570220621 hasAuthorship W1570220621A5089317773 @default.
• W1570220621 hasConcept C126322002 @default.
• W1570220621 hasConcept C141071460 @default.
• W1570220621 hasConcept C2776265017 @default.
• W1570220621 hasConcept C2776301958 @default.
• W1570220621 hasConcept C2776884760 @default.
• W1570220621 hasConcept C2778269268 @default.
• W1570220621 hasConcept C2778959117 @default.
• W1570220621 hasConcept C2779161974 @default.
• W1570220621 hasConcept C2780011451 @default.
• W1570220621 hasConcept C2780868729 @default.
• W1570220621 hasConcept C42219234 @default.
• W1570220621 hasConcept C71924100 @default.
• W1570220621 hasConceptScore W1570220621C126322002 @default.
• W1570220621 hasConceptScore W1570220621C141071460 @default.
• W1570220621 hasConceptScore W1570220621C2776265017 @default.
• W1570220621 hasConceptScore W1570220621C2776301958 @default.
• W1570220621 hasConceptScore W1570220621C2776884760 @default.
• W1570220621 hasConceptScore W1570220621C2778269268 @default.
• W1570220621 hasConceptScore W1570220621C2778959117 @default.
• W1570220621 hasConceptScore W1570220621C2779161974 @default.
• W1570220621 hasConceptScore W1570220621C2780011451 @default.
• W1570220621 hasConceptScore W1570220621C2780868729 @default.
• W1570220621 hasConceptScore W1570220621C42219234 @default.
• W1570220621 hasConceptScore W1570220621C71924100 @default.
• W1570220621 hasIssue "6" @default.
• W1570220621 hasLocation W15702206211 @default.
• W1570220621 hasOpenAccess W1570220621 @default.
• W1570220621 hasPrimaryLocation W15702206211 @default.
• W1570220621 hasRelatedWork W1570220621 @default.
• W1570220621 hasRelatedWork W1982739364 @default.
• W1570220621 hasRelatedWork W1997319204 @default.
• W1570220621 hasRelatedWork W2158381418 @default.
• W1570220621 hasRelatedWork W2236810073 @default.
• W1570220621 hasRelatedWork W2260511505 @default.
• W1570220621 hasRelatedWork W2401571855 @default.
• W1570220621 hasRelatedWork W2410205686 @default.
• W1570220621 hasRelatedWork W2413447664 @default.
• W1570220621 hasRelatedWork W57239253 @default.
• W1570220621 hasVolume "83" @default.
• W1570220621 isParatext "false" @default.
• W1570220621 isRetracted "false" @default.
• W1570220621 magId "1570220621" @default.
• W1570220621 workType "article" @default.